Nicola F. Smith - Concepedia

Author

Nicola F. Smith

National Cancer Institute

Also Known As

N F Smith, N. F. Smith, N.F. Smith, Nicola F Smith, Nicola F. Smith, Nicola Smith

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute Center for Cancer Research Cancer Research UK Institute of Cancer Research Sidney Kimmel Comprehensive Cancer Center

About

Nicola F. Smith is an author at National Cancer Institute specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	191
2	Pharmacology	4	4	191
3	Biochemistry	2	2	118
4	Cell Biology	1	1	97
5	Antimicrobial Pharmacodynamics	1	1	21

Nicola F. Smith

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel Nicola F. Smith, Milin Acharya, Neil Desai, Cancer Biology & Therapy	2005	236
Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity Lindsay Stimson, Martin Rowlands, Yvette Newbatt, Molecular Cancer Therapeutics	2005	221
Variants in the SLCO1B3 Gene: Interethnic Distribution and Association with Paclitaxel Pharmacokinetics Nicola F. Smith, Steven G. E. Marsh, T J Scott-Horton, Clinical Pharmacology & Therapeutics	2006	162
Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine Donald Lavelle, Kestis Vaitkus, Yonghua Ling, Blood	2011	100
Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026 Bernard Nutley, Nicola F. Smith, Angela Hayes, British Journal of Cancer Radiation EffectRadiation ExposurePharmacotherapyPhysiologically-based Pharmacokinetic ModelingTumor Biology	2005	97
Effect of Common<i>CYP3A4</i>and<i>CYP3A5</i>Variants on the Pharmacokinetics of the Cytochrome<i>P</i>450 3A Phenotyping Probe Midazolam in Cancer Patients Erin R. Lepper, Sharyn D. Baker, Matt Permenter, Clinical Cancer Research	2005	71
Recent advances in pharmacogenetic approaches to anticancer drug development Nicola F. Smith, William D. Figg, Alex Sparreboom Drug Development Research Chemoprevention StrategyPharmacotherapyUgt FamilySystem PharmacologyPhysiologically-based Pharmacokinetic Modeling	2004	52
Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors Nicola F. Smith, Angela Hayes, Karen James, Molecular Cancer Therapeutics	2006	38
Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100 Nicola F. Smith, Sharyn D. Baker, Frank J. Gonzalez, British Journal of Cancer	2008	28
Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals? Alan Winston, Anton Pozniak, Nicola F. Smith, AIDS	2004	26

Page 1